arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Incyte Corporation

INCY Health Care Biotechnology: Commercial Physical & Biological Resarch
$126.75
Today
as of Sep 4, 16:50 ET
Last 30 days -2.45% Jul 28 → Sep 04
$117.46 $120.81 $124.15 $127.50 $130.85 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$126.46
High
$128.04
Low
$126.04
Volume
$1M
Avg Vol
$2M
Mkt Cap
$24.0B
P/E (TTM)
22.13
Beta
—
52w High
$132.60
52w Low
$81.09
Div Yield
—
Shares Out
$200M

Recent Press Releases & News last 60 days · 25 items

Sep 1 · 12:00 PR Business Wire
Incyte to Present at Upcoming Investor Conferences
Aug 30 · 13:05 Simply Wall St.
Incyte (INCY) Just Moved, So What Is Drawing Attention Now?
Aug 30 · 06:17 Simply Wall St.
Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$81
$133
89% of range
Avg surprise (last 2)
+16.8%
Avg reaction (last 1)
+1.5%
100% positive
Latest IV / EM
34%
EM ±5.2% · $125 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.04$-1.00$0.04$1.07$2.11 Actual $0.50Actual $0.10Actual $0.90Actual $0.76Actual $0.75Actual $-2.04Actual $0.54Actual $0.89Est $0.75Actual $1.31Est $1.14Actual $2.11Actual $1.47 SepMarJunSepMarJunSepMar/2025Jun/2025SepMar
Revenue vs Net Income Revenue Net income
$-445M$25M$495M$965M$1.4B Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Mar 31, 2026Mar 2026 $1.47 — — — — financials
Tue Sep 30, 2025Sep 2025 $2.11 — — — — financials
Tue Jul 29, 2025Jun/2025 $1.31 $1.14 +14.9% — — earnings
Tue Apr 29, 2025Mar/2025 $0.89 $0.75 +18.7% — +1.5% earnings
Mon Sep 30, 2024Sep 2024 $0.54 — — — — financials
Sun Jun 30, 2024Jun 2024 $-2.04 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.75 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.76 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.90 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.10 — — — — financials
Fri Sep 30, 2022Sep 2022 $0.50 — — — — financials

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue$1.27B—$1.37B$1.22B$1.05B—$1.14B$1.04B
Cost of revenue$105M—$99M$79M$73M—$86M$77M
Gross profit————————
Operating income$301M—$444M$530M$205M—$146M$-478M
Net income$303M—$424M$405M$158M—$106M$-445M
EPS (diluted)$1.47—$2.11$2.04$0.80—$0.54$-2.04

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$3.46B$3.10B$2.46B$1.95B$1.94B$1.69B$1.30B$987M
Inventory$116M$101M$83M$83M$64M$59M$70M$101M
Total current assets$5.48B$5.02B$4.28B$3.64B$3.51B$3.24B$2.81B$2.57B
Total assets$7.34B$6.96B$6.33B$5.82B$5.75B$5.44B$5.01B$4.66B
Long-term debt————————
Total liabilities$1.72B$1.79B$1.68B$1.65B$2.08B$2.00B$1.84B$1.66B
Total equity$5.62B$5.17B$4.65B$4.17B$3.67B$3.45B$3.17B$3.00B

Implied volatility — last 90 days

27%43%59%76%92% Jun 07 — IV 56% · EM ±7.8%Jun 08 — IV 53% · EM ±7.0%Jun 09 — IV 52% · EM ±6.5%Jun 10 — IV 57% · EM ±6.8%Jun 11 — IV 49% · EM ±5.4%Jun 12 — IV 40% · EM ±4.1%Jun 15 — IV 47% · EM ±3.4%Jun 16 — IV 54% · EM ±3.2%Jun 17 — IV 56% · EM ±2.3%Jun 19 — IV 28% · EM ±6.1%Jun 22 — IV 35% · EM ±7.4%Jun 23 — IV 28% · EM ±5.7%Jun 24 — IV 30% · EM ±6.0%Jun 25 — IV 30% · EM ±5.9%Jun 26 — IV 36% · EM ±6.9%Jun 29 — IV 33% · EM ±5.8%Jun 30 — IV 29% · EM ±5.1%Jul 01 — IV 33% · EM ±5.6%Jul 02 — IV 35% · EM ±5.6%Jul 03 — IV 36% · EM ±5.6%Jul 06 — IV 38% · EM ±5.3%Jul 07 — IV 35% · EM ±4.6%Jul 08 — IV 42% · EM ±5.2%Jul 09 — IV 36% · EM ±4.2%Jul 10 — IV 39% · EM ±4.3%Jul 13 — IV 40% · EM ±3.3%Jul 14 — IV 34% · EM ±2.5%Jul 15 — IV 53% · EM ±3.1%Jul 16 — IV 75% · EM ±3.1%Jul 20 — IV 37% · EM ±8.7%Jul 21 — IV 39% · EM ±9.2%Jul 22 — IV 36% · EM ±8.3%Jul 23 — IV 40% · EM ±9.0%Jul 24 — IV 39% · EM ±8.6%Jul 27 — IV 41% · EM ±8.7%Jul 28 — IV 36% · EM ±7.4%Jul 29 — IV 34% · EM ±6.8%Jul 30 — IV 33% · EM ±6.5%Jul 31 — IV 33% · EM ±6.4%Aug 03 — IV 30% · EM ±5.4%Aug 04 — IV 33% · EM ±5.7%Aug 05 — IV 35% · EM ±5.9%Aug 06 — IV 42% · EM ±6.8%Aug 07 — IV 39% · EM ±6.0%Aug 10 — IV 34% · EM ±4.7%Aug 11 — IV 36% · EM ±4.7%Aug 12 — IV 37% · EM ±4.6%Aug 13 — IV 33% · EM ±3.9%Aug 14 — IV 40% · EM ±4.5%Aug 17 — IV 43% · EM ±3.6%Aug 18 — IV 33% · EM ±2.4%Aug 19 — IV 38% · EM ±2.3%Aug 20 — IV 92% · EM ±3.9%Aug 24 — IV 37% · EM ±7.7%Aug 25 — IV 31% · EM ±6.3%Aug 26 — IV 31% · EM ±6.2%Aug 27 — IV 36% · EM ±7.1%Aug 28 — IV 35% · EM ±6.7%Aug 31 — IV 38% · EM ±6.8%Sep 01 — IV 32% · EM ±5.5%Sep 02 — IV 36% · EM ±6.0%Sep 03 — IV 38% · EM ±6.2%Sep 04 — IV 34% · EM ±5.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in